This research study is studying to see if a blood test, collected at different times during
the treatment of metastatic non-small lung cancer, can be used to detect early response in
patients being treated with pembrolizumab and use that information to determine whether
patients should continue treatment with pembrolizumab or switch treatment to pembrolizumab in
combination with chemotherapy.
The names of the study drugs involved in this study are:
- Pembrolizumab
- Platinum doublet chemotherapy, which may include the following:
- Carboplatin and pemetrexed
- Carboplatin and paclitaxel
The name of the blood test:
- InVision (Inivata, Ltd.)